Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BBT001
- Development stage
- Phase 2
- Lead developer
- Bambusa Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Parenteral (likely Intravenous Or Subcutaneous; Specific Route Not Yet Disclosed)
01
Overview
BBT001 is a novel, half-life extended tetravalent bispecific antibody developed by Bambusa Therapeutics for the treatment of atopic dermatitis and potentially other inflammatory skin diseases. It simultaneously targets interleukin-4 receptor alpha (IL-4Rα) and interleukin-31 (IL-31), two clinically validated but non-overlapping pathways implicated in the pathogenesis of atopic dermatitis. By engaging both targets, BBT001 aims to deliver faster onset of symptom relief, superior efficacy, and improved dosing convenience compared to currently approved biologics for atopic dermatitis. The drug is currently in Phase 1 clinical trials with initial studies underway in Australia and the United States[1][2][3][5][9].
02
Targets
IL31 (IL-31)IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on BBT001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BBT001.